Aktis Oncology (Series B)

Funding Details
Awarder
Inbox
Date Award
October 17, 2024
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$175,000,000

Company Info
Organizations Involved
Bristol Myers Squibb, Eli Lilly and Company, Merck & Co., Inc.
Company Description
Aktis Oncology is a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors.
Market
Clinical-stage oncology treatments
Location
Boston, MA, USA
Coinvestors
RA Capital Management, RTW Investments, Janus Henderson Investors, T. Rowe Price Associates, Avidity Partners, Bristol Myers Squibb, Eli Lilly and Company, MRL Ventures Fund

Links